- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about LSD Therapy
Recent news which mentions LSD Therapy
Can LSD Therapy Calm Anxious Dogs? First-Of-Its-Kind Study Uncovers New Possibilities
September 27, 2024
From Benzinga
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
March 27, 2024
From Benzinga
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
March 08, 2024
From Benzinga
From Benzinga
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
February 28, 2024
Tickers
MNMD
From Benzinga
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued
January 11, 2024
From Benzinga
Federico Fellini's LSD Journey: How It Inspired Some Of The Greatest Films Of All Time
August 23, 2023
From Benzinga
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
June 28, 2023
From Benzinga
From Benzinga
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
May 19, 2023
Tickers
MNMD
From Benzinga
80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial
April 17, 2023
Tickers
MNMD
From Benzinga
LSD's Impact On The Body's Cannabinoid And Microorganisms Systems, New Study Sheds Light
January 13, 2023
From Benzinga
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
November 29, 2022
From Benzinga
LSD Microdosing Yields Positive Outcomes In Phase 1 Study, More Trials On Depression & Existential Distress
November 04, 2022
Tickers
BLRZF
From Benzinga
Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
September 27, 2022
Tickers
BETRF
From Benzinga
This LSD Phase 2 Clinical Trial Is Showing Positive Results For Treatment Of Generalized Anxiety
September 08, 2022
Tickers
MNMD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.